Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$3.94 USD
-0.04 (-1.01%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GLUE 3.94 -0.04(-1.01%)
Will GLUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLUE
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
Other News for GLUE
Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update